Introduction
Intertrigo is a superficial inflammatory skin condition that affects flexural surfaces, such as the axillae, abdominal folds, and perineum. This condition is often triggered or aggravated by warm temperatures, friction, moisture, maceration, and poor ventilation.[1] The Latin origins of the term "intertrigo"—inter (meaning "between") and terere (meaning "to rub")—illustrate the physiology of the condition.[2] Intertrigo often becomes secondarily infected, particularly by Candida, although other viral or bacterial pathogens also contribute to its pathogenesis (see Image. Candida-Associated Intertrigo).
Intertrigo can occur at any age and is primarily diagnosed clinically; in more complex cases, further evaluation, such as culturing or skin scraping, may be needed to identify specific pathogens. Intertrigo typically presents as erythematous patches of varying intensity, which may progress to erosions and secondary lesions due to irritation or manipulation.[3]
Etiology
Register For Free And Read The Full Article
- Search engine and full access to all medical articles
- 10 free questions in your specialty
- Free CME/CE Activities
- Free daily question in your email
- Save favorite articles to your dashboard
- Emails offering discounts
Learn more about a Subscription to StatPearls Point-of-Care
Etiology
Mechanical factors and secondary infections are vital contributors to intertrigo. Heat and maceration have central roles in facilitating this process. The skin folds experience constant friction, leading to irritation and, at times, erosion of the inflamed skin. Additionally, moisture accumulates in the affected intertriginous areas, creating an environment conducive to secondary infections. Candida species thrive in warm, high-moisture conditions, making them a common cause of secondary infections in intertrigo cases.
Furthermore, patients with diabetes often have elevated pH levels in intertriginous areas, which contributes to their higher prevalence of intertrigo.[4] Also, gram-positive and gram-negative bacteria and other fungi and viruses are common causes of secondary infections in some cases.[5][6][7]
Epidemiology
Intertrigo can affect individuals of all ages, from infancy to advanced age. The inflammatory condition often presents as a variation of diaper dermatitis in infants. Furthermore, factors such as a naïve or weakened immune system, limited mobility, and urinary or fecal incontinence contribute to the skin manifestations and their complications.[3] Obesity and diabetes are conditions that increase the likelihood of developing intertrigo.[6] The condition is most prevalent in geographic areas with hot and humid climates. Additionally, no ethnic or gender predilection has been observed.
Pathophysiology
Environmental and genetic factors play a significant role in the development of intertrigo. Friction between adjacent skin surfaces is a key factor leading to epidermal inflammation. Flexural areas also tend to have higher surface temperatures than other body parts, which, when combined with moisture and sweat build-up, contribute to the maceration of the stratum corneum and epidermis. Moreover, the integumentary system contains bacteria and yeast that thrive in this environment and can overgrow under these conditions, making infections a common occurrence.[5][6][7]
Histopathology
No characteristic histological changes are typically seen in intertrigo, although some cases may show mild spongiosis in the epidermis.
History and Physical
Intertrigo typically presents with a chronic, subtle onset of pruritus, burning, tingling, and pain in skin folds and flexural surfaces. An acute change in symptoms may indicate a secondary infection with Candida albicans, bacteria, or other pathogens. The patient is often engaged in activities that result in skin surfaces rubbing together. Hot and humid environmental conditions further aggravate the condition, contributing to its pathology. As a result, intertrigo tends to have a higher incidence during certain seasons.
Hyperhidrosis, often triggered by strenuous exercise, significantly contributes to this inflammatory condition. Predisposing factors such as obesity, diabetes, incontinence, urethral discharge, and draining wounds all create a warm, moist, and occluded environment that promotes the development of intertrigo.[8]
Intertrigo is most prevalent among patients with obesity, though it can affect individuals of any body mass index (BMI) depending on other factors. The increased surface area in patients with obesity accentuates the folds and creases of the body, creating an environment conducive to higher temperatures.
The initial presentation noted during a skin examination typically reveals a mildly erythematous patch on both sides of the skin fold. The degree of inflammation varies based on location, duration, and the presence of secondary infection. Over time, the erythematous patches may develop erosions, maceration, fissures, crusting, and weeping.
If pustules, crusts, or vesicles are visible, secondary infection should be considered. Satellite papules and pustules are pathognomonic if Candida spp are suspected. A bluish-green tint may indicate infection with Pseudomonas.[9] Bacterial intertrigo often presents with weeping, intense erythema, and tenderness.[5] In cases of interdigital intertrigo, Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum are commonly implicated organisms.[10]
Evaluation
Further evaluation beyond clinical diagnosis may be needed to determine the exact cause and most effective treatment. If a bacterial infection is suspected, the lesion can be cultured. For fungal infections, a skin scraping from the active margin of the lesion should be taken, and a 20% potassium hydroxide (KOH) solution should be added to aid detection. Under light microscopy, the presence of hyphae or budding yeast confirms a fungal infection. If the presentation is atypical or treatment has failed, a biopsy should be considered for further investigation.
A Wood lamp can aid in detecting infections caused by Pseudomonas or erythrasma (Corynebacterium minutissimum).[11] In cases of difficult-to-treat or recurrent episodes, fasting blood glucose levels should be obtained to evaluate for potential underlying diabetes.
Treatment / Management
Intertrigo can be effectively treated by identifying and addressing the underlying cause of the condition. As mentioned above, the offending factor or agent should be minimized or eliminated. If the rash is due to an infection, appropriate antimicrobial therapy should be initiated. In cases of simple intertrigo, drying agents such as antiperspirants can help reduce moisture. After physical activity that leads to excessive perspiration, bathing or showering, followed by gentle drying with a soft towel, is recommended.[12]
Triple paste, which contains aluminum acetate solution, zinc oxide, and petrolatum, is an effective antiperspirant that reduces friction and alleviates skin irritation. Staying cool by wearing loose clothing and working in air-conditioned environments can help prevent the rash. Other effective preventative measures include using absorbent powders combined with a 1:40 aqueous solution of aluminum triacetate and applying wet tea bags. While absorbent diapers are particularly effective at reducing moisture, petrolatum ointment or cream is also a safe and effective option for treating diaper dermatitis if needed.
Topical treatments such as mupirocin or bacitracin may be effective for lesions infected with mild bacteria. Flucloxacillin or erythromycin, which targets gram-positive bacteria such as Staphylococcus or Streptococcus, should be prescribed if oral medication is necessary. For yeast or fungal infections associated with intertrigo, topical options such as clotrimazole, ketoconazole, and oxiconazole are effective. Topical nystatin is specifically effective for candidal intertrigo.
Topical treatments should be applied twice daily until the rash resolves. For resistant fungal infections, oral fluconazole at a dosage of 100 to 200 mg daily for 7 days may be effective.[13] Low-dose steroids, such as hydrocortisone cream, can be considered for their anti-inflammatory properties, although they are not always necessary. A lower-strength steroid is preferred to prevent atrophy in the already thinner epidermis of the flexural surfaces.[14][15](A1)
Differential Diagnosis
The differential diagnosis for intertrigo is extensive, as many other conditions can occur in the flexural surfaces. However, it is crucial to rule out infections and identify the specific infectious agent to provide the appropriate antimicrobial therapy needed to eliminate the offending organism. Bacteria, viruses, dermatophytes, and Candida species can all cause intertrigo or provoke a secondary infection.[16] Once an infection has been ruled out, further investigation of other similarly presenting conditions commonly found in the flexural areas can proceed.
More common conditions, such as seborrheic dermatitis, irritant or allergic contact dermatitis, atopic dermatitis, inverse psoriasis, pemphigus, scabies, metabolic derangements, and malignancies, frequently present in skin folds and can mimic intertrigo.[17] Nonetheless, intertrigo remains primarily a clinical diagnosis characterized by the findings and clinical picture previously described.
Prognosis
The prognosis is positive for most patients, especially when underlying risk factors are addressed to reduce intertrigo outbreaks. However, if risks such as diabetes and obesity are not effectively managed, the condition is likely to relapse frequently.
Complications
The primary complications associated with intertrigo are secondary infections, as discussed previously. Patients should seek clinical guidance to properly manage rashes to optimize infection prevention. If left untreated, the rash may progress to cellulitis.[18]
Furthermore, sepsis can arise from hidden ulcers that develop in unsupervised patients or individuals with obesity. Contact dermatitis may be a secondary reaction to topical agents used to treat the rash. Prolonged steroid use can lead to atrophy and striae in the thinned epidermis of the flexural surfaces.
Consultations
A dermatologist should be consulted for further management if there is any doubt about the diagnosis or if a rash has not responded to treatment.
Deterrence and Patient Education
Weight loss and weight management, proper hygiene, glycemic control for patients with diabetes, and strategies to reduce friction from skin-to-skin contact should be discussed with patients and their families to help prevent intertrigo.[19]
Pearls and Other Issues
A combination of infectious and inflammatory components typically exists, particularly observed in inguinal intertrigo. Infections are often unilateral and asymmetrical, while inflammatory disorders tend to be symmetrical. [20]
Enhancing Healthcare Team Outcomes
An interprofessional team approach involving multidisciplinary healthcare providers is the most effective way to manage intertrigo. Clinicians and pharmacists play crucial roles in successfully treating the rash. Clinicians should emphasize and educate patients on preventive risk factors and effective management strategies to address current cases and prevent future occurrences of intertrigo. Additionally, clinicians can consult pharmacists when needed to assist with different formulations of topical and oral therapies for specific infectious etiologies.
Media
(Click Image to Enlarge)
References
Voegeli D. Intertrigo: causes, prevention and management. British journal of nursing (Mark Allen Publishing). 2020 Jun 25:29(12):S16-S22. doi: 10.12968/bjon.2020.29.12.S16. Epub [PubMed PMID: 32579453]
Wolf R, Oumeish OY, Parish LC. Intertriginous eruption. Clinics in dermatology. 2011 Mar-Apr:29(2):173-9. doi: 10.1016/j.clindermatol.2010.09.009. Epub [PubMed PMID: 21396557]
Kalra MG, Higgins KE, Kinney BS. Intertrigo and secondary skin infections. American family physician. 2014 Apr 1:89(7):569-73 [PubMed PMID: 24695603]
Yosipovitch G, Tur E, Cohen O, Rusecki Y. Skin surface pH in intertriginous areas in NIDDM patients. Possible correlation to candidal intertrigo. Diabetes care. 1993 Apr:16(4):560-3 [PubMed PMID: 8462378]
Chiriac A, Murgu A, Coroș MF, Naznean A, Podoleanu C, Stolnicu S. Intertrigo Caused by Streptococcus pyogenes. The Journal of pediatrics. 2017 May:184():230-231.e1. doi: 10.1016/j.jpeds.2017.01.060. Epub 2017 Feb 22 [PubMed PMID: 28237374]
Metin A, Dilek N, Bilgili SG. Recurrent candidal intertrigo: challenges and solutions. Clinical, cosmetic and investigational dermatology. 2018:11():175-185. doi: 10.2147/CCID.S127841. Epub 2018 Apr 17 [PubMed PMID: 29713190]
Adışen E, Önder M. Viral infections of the folds (intertriginous areas). Clinics in dermatology. 2015 Jul-Aug:33(4):429-36. doi: 10.1016/j.clindermatol.2015.04.004. Epub 2015 Apr 8 [PubMed PMID: 26051057]
Ndiaye M, Taleb M, Diatta BA, Diop A, Diallo M, Diadie S, Seck NB, Diallo S, Ndiaye MT, Niang SO, Ly F, Kane A, Dieng MT. [Etiology of intertrigo in adults: A prospective study of 103 cases]. Journal de mycologie medicale. 2017 Mar:27(1):28-32. doi: 10.1016/j.mycmed.2016.06.001. Epub 2016 Aug 21 [PubMed PMID: 27554869]
Level 3 (low-level) evidenceKalkan G, Duygu F, Bas Y. Greenish-blue staining of underclothing due to Pseudomonas aeruginosa infection of intertriginous dermatitis. JPMA. The Journal of the Pakistan Medical Association. 2013 Sep:63(9):1192-4 [PubMed PMID: 24601205]
Level 3 (low-level) evidenceGrosshans E, Schwaab E, Samsoen M, Grange D, Koenig H, Kremer M. [Clinical aspects, epidemiology and economic impact of foot epidermomycosis in an industrial milieu]. Annales de dermatologie et de venereologie. 1986:113(6-7):521-33 [PubMed PMID: 2949683]
Level 2 (mid-level) evidenceAgrawal I, Panda M. Utility of Wood's Lamp in Intertrigo. Indian dermatology online journal. 2021 Nov-Dec:12(6):948-949. doi: 10.4103/idoj.IDOJ_957_20. Epub 2021 Aug 2 [PubMed PMID: 34934747]
Verzì AE, Nasca MR, Dall'Oglio F, Cosentino C, Micali G. A novel treatment of intertrigo in athletes and overweight subjects. Journal of cosmetic dermatology. 2021 Apr:20 Suppl 1(Suppl 1):23-27. doi: 10.1111/jocd.14097. Epub [PubMed PMID: 33934472]
Chirag D, Mari A, Norbert B, Almut BA. "Refractory Intertrigo" in an Elderly Woman. Indian dermatology online journal. 2020 Jan-Feb:11(1):105-107. doi: 10.4103/idoj.IDOJ_2_19. Epub 2020 Jan 13 [PubMed PMID: 32055523]
Del Rosso JQ. Adult seborrheic dermatitis: a status report on practical topical management. The Journal of clinical and aesthetic dermatology. 2011 May:4(5):32-8 [PubMed PMID: 21607192]
Hoeger PH, Stark S, Jost G. Efficacy and safety of two different antifungal pastes in infants with diaper dermatitis: a randomized, controlled study. Journal of the European Academy of Dermatology and Venereology : JEADV. 2010 Sep:24(9):1094-8. doi: 10.1111/j.1468-3083.2010.03735.x. Epub 2010 Jun 9 [PubMed PMID: 20553355]
Level 1 (high-level) evidenceHonig PJ, Frieden IJ, Kim HJ, Yan AC. Streptococcal intertrigo: an underrecognized condition in children. Pediatrics. 2003 Dec:112(6 Pt 1):1427-9 [PubMed PMID: 14654624]
Level 3 (low-level) evidenceWilmer EN, Hatch RL. Resistant "candidal intertrigo": could inverse psoriasis be the true culprit? Journal of the American Board of Family Medicine : JABFM. 2013 Mar-Apr:26(2):211-4. doi: 10.3122/jabfm.2013.02.120210. Epub [PubMed PMID: 23471936]
Level 3 (low-level) evidenceVanhooteghem O, Szepetiuk G, Paurobally D, Heureux F. Chronic interdigital dermatophytic infection: a common lesion associated with potentially severe consequences. Diabetes research and clinical practice. 2011 Jan:91(1):23-5. doi: 10.1016/j.diabres.2010.09.016. Epub 2010 Oct 29 [PubMed PMID: 21035887]
Level 3 (low-level) evidenceRomanelli M, Voegeli D, Colboc H, Bassetto F, Janowska A, Scarpa C, Meaume S. The diagnosis, management and prevention of intertrigo in adults: a review. Journal of wound care. 2023 Jul 2:32(7):411-420. doi: 10.12968/jowc.2023.32.7.411. Epub [PubMed PMID: 37405940]
da Ponte MN, Riveros R, Goiburu B, Aldama A. Inguinal intertrigo: Infectious or inflammatory? Enfermedades infecciosas y microbiologia clinica (English ed.). 2024 Aug-Sep:42(7):388-389. doi: 10.1016/j.eimce.2024.02.007. Epub 2024 Feb 12 [PubMed PMID: 38350836]